EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, IOVA: Iovance Biotherapeutics Inc

12 Dec 25 15:59
LAST:

2.205

CHANGE:
 0.05		OPEN:
2.250		HIGH:
2.300		ASK:
6.500		VOLUME:
9.84M
CHG(%):
2.22		PREV:
2.250		LOW:
2.170		BID:
4.850		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
12 Dec 252.2402.2602.1702.20010.62M
11 Dec 252.2602.3202.2402.25013.86M
10 Dec 252.2302.2902.1752.2607.33M
09 Dec 252.2902.3252.2402.2507.04M
08 Dec 252.2002.3402.1602.31014.08M
05 Dec 252.2002.2502.1752.2006.62M
04 Dec 252.2002.2402.1602.2008.75M
03 Dec 252.1402.2352.1402.2107.85M
02 Dec 252.2602.2692.1302.1357.76M
01 Dec 252.4202.4202.2202.23011.8M

PROFILE

Name:Iovance Biotherapeutics Inc
About:Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It develops lifileucel for treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001, an antibody cytokine engrafted protein for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Sector:Healthcare
Industry:Biotechnology
Address:825 Industrial Road, San Carlos, CA, United States, 94070
Website:https://www.iovance.com
CUSIP:37182R102
CIK:0001425205
ISIN:US4622601007
FIGI:BBG000FTLBV7
LEI:549300220Z2GHH33XL82

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-1.52 
Forward P/E:-2.40 
PEG Ratio:0.52 
Price to Sales:2.95 
Price to Book:0.96 
Profit Margin:-1.61 
Operating Margin:-1.90 
Return on Assets:-0.27 
Return on Equity:-0.53 
EPS Ratio:-1.21 
Revenue:241.52M 
Shares:361.85M 
Market Cap:797.89M 

TECHNICAL INDICATORS

MA5:2.252.2%
MA10:2.220.9%
MA20:2.314.6%
MA50:2.241.7%
MA100:2.335.6%
MA200:2.4913.1%
STO9:31.71
STO14:15.85 
RSI14:48.02
WPR14:-82.19 
MTM14:-0.30
ROC14:-0.12 
ATR:0.13 
Week High:2.346.1%
Week Low:2.162.1%
Month High:2.7223.4%
Month Low:2.0913.1%
Year High:8.56288.2%
Year Low:1.6434.6%
Volatility:10.98 

RECENT SPLITS

Date Ratio
26 Sep 20131-100
26 May 201023999-1000